Health Catalyst (HCAT) Q3 2026 earnings review
Health Catalyst clears its debt, but margins fall after divestiture
Health Catalyst paid off all its debt by selling its best profit engine, leaving the remaining hospital software business shrinking and near breakeven. Third-quarter sales fell 26% to $56 million after the Vitalware divestiture and customer losses during a software platform migration. New chief executive Simeon Kohl — the company's third leader this year — beat the third-quarter profit plan and kept the full-year outlook unchanged, which by our math points to an operating loss in the fourth quarter.
| Revenue | $56.3M -26% from a year ago (Vitalware sold July 31) |
|---|---|
| Adjusted EBITDA | $0.78M above $0–0.5M plan; down 94% from a year ago |
| Gross margin, excluding one-offs | 44% 53% a year ago |
| Full-year outlook | Unchanged implies -$1.6M Q4 Adjusted EBITDA by our math |
⚖️ Verdict: 🔴 Bearish
The story got worse because gross margins in both software and consulting dropped sharply and the held full-year target points to a deeper fourth-quarter loss than it did three months ago. Consulting barely broke even before overhead as revenue fell 36%, and another abrupt chief executive change adds uncertainty right in the middle of the turnaround. On the plus side, the company now sits on $79 million in cash and short-term investments with zero debt, and quarterly overhead cuts met the $3 million target.
The question now is whether the remaining business can return to operating profit in 2027 or whether customers moving off the old data platform will keep shrinking software revenue and cash. Either the migration losses fade and software margins stabilize near 60%, or hospital clients switch to general-purpose cloud platforms and force another round of cost cuts. The fourth-quarter report — bringing the first full quarter without Vitalware, annual bookings, and the 2027 outlook — will tell.
🐂 Bull Case
Vitalware Sale Eliminated All Long-Term Debt
Health Catalyst, which sells data software and consulting to hospitals, sold its Vitalware revenue-management unit on July 31 for $146.3 million. The healthcare software group used the $144.5 million in net cash proceeds and cash on hand to "voluntarily repay in full all outstanding obligations under the Credit Agreement and terminate the agreement". That repayment wiped out $153.5 million of debt that stood on the books in June.
Paying off the loan removes roughly $19 million in yearly interest costs and frees the business from lender rules while it shrinks. The Utah-based company ended September with $79.0 million in cash and short-term investments and zero debt, though it booked a $9.5 million one-off charge for early loan payoff fees and write-offs.
What to watch: total cash and short-term investments at year-end. Holding that balance near $79 million in the fourth quarter would show that interest savings are offsetting lower operating profits.
Operating Cost Cuts Hit the $3 Million Target
Earlier this year Health Catalyst launched Project Nexus, a restructuring plan to shrink its workforce and cut quarterly overhead by about $3 million compared with the first quarter. In the third quarter, operating expenses excluding one-offs fell to $24.1 million, down $3.2 million from $27.3 million in the first quarter by our math.
Reported sales and marketing spending dropped 40% from a year ago to $8.6 million, and research and development fell 23% to $9.5 million. Because revenue shrank 26% after the Vitalware sale, overhead excluding one-offs still rose to 43% of sales from 37% a year ago.
What to watch: fourth-quarter operating expenses excluding one-offs. Another reading at or below $24 million would confirm that the cost cuts are permanent rather than a one-quarter dip after the divestiture.
🐻 Bear Case
Held Outlook Implies Fourth-Quarter Operating Losses
"We delivered a third quarter above the high end of our revenue and Adjusted EBITDA guidance, and we are reaffirming our full-year outlook," chief executive Simeon Kohl said. Adjusted EBITDA — operating profit before interest, taxes, depreciation, stock pay and one-off charges — reached $0.78 million in the third quarter, beating the $0 to $0.5 million plan.
Yet keeping the full-year target at $18.0 million to $18.5 million turns that third-quarter beat into a deeper fourth-quarter loss. Across the first nine months of 2026, the hospital software provider has already earned $19.84 million in Adjusted EBITDA by our math ($9.14 million in Q1, $9.92 million in Q2, and $0.78 million in Q3).
To land inside the full-year range, fourth-quarter Adjusted EBITDA must come in between negative $1.34 million and negative $1.84 million by our math. That is worse than the negative $0.56 million to negative $1.56 million implied three months ago, because the third-quarter beat was not added to the annual target. Without Vitalware, the remaining business is entering 2027 losing money on an operating basis.
What to watch: the initial 2027 Adjusted EBITDA outlook on the fourth-quarter report. A positive full-year target will show whether the fourth-quarter loss is a brief trough or the new baseline for the continuing business.
Software and Services Margins Drop as Revenue Shrinks
Health Catalyst is moving customers from its older Data Operating System (DOS) to Ignite, its newer cloud data platform, while winding down less profitable consulting contracts. Combined with the sale of high-margin Vitalware on July 31, those shifts pushed total gross margin down 8.5 percentage points from a year ago to 31%, or 44% excluding one-offs (down 9 points).
- Technology gross margin excluding one-offs: 61%, down 7.6 percentage points from a year ago as cost of making the software rose 6.7 points of segment sales
- Professional services gross margin: negative 3% on a reported basis and 2% excluding one-offs, down 17.4 points as delivery costs hit 103% of consulting sales
- Professional services revenue: $15.6 million, down 36% from a year ago, or a $62.4 million yearly pace on its way toward a planned $55 million exit rate
Consulting revenue is falling faster than the company is cutting consulting staff, leaving the services unit barely breaking even before overhead. Meanwhile, duplicate cloud hosting costs during customer migrations continue to squeeze the technology unit.
What to watch: technology gross margin excluding one-offs in the fourth quarter, the first full period without Vitalware. A drop below 60% would show that migration costs are hurting the software core more than the divestiture alone.
Third CEO in a Year Takes Over During Platform Migration
Simeon Kohl delivered the third-quarter commentary as President and Chief Executive Officer, replacing Ben Albert, who had just taken over from longtime chief Dan Burton at the start of 2026. "Our immediate priority is to strengthen the foundation of the business, with a focus on retaining the clients we serve and developing a path to generating durable, profitable revenue," Kohl said.
Changing leaders twice in less than a year adds execution risk while the company tries to keep hospitals from leaving during the switch from DOS to Ignite. The release notes that revenue and margins fell "primarily as a result of the divestiture of the Vitalware Business on July 31, 2026 and headwinds related to the migration from DOS to Ignite".
What to watch: whether Kohl keeps the end-of-2027 completion target for the Ignite migration and the $22 million to $26 million full-year bookings target at year-end. Any reset of those targets would signal another strategic overhaul under the new chief.
Risks this quarter didn't answer
Four standing issues from the company's strategic reset received no updated figures in the third-quarter earnings release.
- AI intelligence products: the company pitches an AI software layer to offset commoditized data storage, but gives no product revenue or adoption numbers; annual bookings ($22–26 million target) arrive in the fourth-quarter report.
- At-risk recurring revenue: no update in the release on the $52 million of customer contracts previously flagged as at risk from platform migrations; the quarterly filing or call will show if churn worsened.
- Hospital client budgets: management still lists macroeconomic and regulatory pressures in risk factors, with no new detail on how Medicaid and research funding cuts are affecting sales cycles.
- Goodwill write-downs: no new impairment charge hit in the third quarter after $122.5 million of write-offs in the first half left $11.1 million of goodwill on the balance sheet.
💲 Other KPIs
Deferred revenue — cash customers have paid upfront for software and services not yet delivered — fell 27.1% from $59.2 million a year ago after Vitalware left the balance sheet. Measured against the $43.0 million continuing balance at the end of June, it held steady (+0.4% by our math).
By our math, subtracting first-half cash flows from nine-month totals shows the company burned $1.9 million in operating cash and $6.3 million in free cash flow (including $4.4 million of capitalized software and equipment) during Q3. That reversed a $7.8 million free cash flow surplus in the first half.
Weighted-average basic shares rose 7.1% from 70.4 million a year ago and 1.9% from the second quarter. Stock-based compensation and prior acquisition share issuances keep expanding the share count while the buyback program remains paused at zero.
🔮 Guidance
Unchanged. The full-year plan still points to a 20.5% revenue drop at the middle of the range after selling Vitalware. By our math, subtracting $197.5 million of nine-month sales leaves $48.5 million to $51.5 million for Q4 (down 33.1% from a year ago at the middle of the range), the first full quarter without Vitalware.
Unchanged. The outlook still calls for a 55.9% drop in full-year Adjusted EBITDA from $41.4 million in 2025. Because nine-month Adjusted EBITDA already totals $19.84 million after Q3 beat its range by $0.28 million, the held target leaves negative $1.34 million to negative $1.84 million for Q4 by our math.
❓ Key Questions
Why Did Chief Executive Ben Albert Leave After Two Quarters?
Simeon Kohl is the company's third chief executive in 2026. Investors need to know whether Albert's departure stems from disagreements over Project Nexus or deeper customer losses during the Ignite platform migration.
What Revenue Did Vitalware Contribute in July?
The Vitalware sale closed on July 31, so third-quarter technology revenue of $40.7 million still includes one month of the sold unit. Without that July figure, investors cannot measure the continuing software unit's sequential drop.
Why Was the Q3 Profit Beat Not Added to 2026?
Third-quarter Adjusted EBITDA beat the midpoint of the plan by $0.53 million, yet management left the full-year outlook unchanged. That implies fourth-quarter operating losses widened by the exact size of the third-quarter beat.
When Will Consulting Staff Cuts Catch Up to Falling Sales?
Professional services gross margin excluding one-offs dropped to 2% in the third quarter from 22% in the second quarter. Management has not said when consulting delivery costs will shrink to match the planned $55 million revenue pace.